HK Stock Market Move | "GENSCRIPT BIO (01548) rose more than 8% in early trading, Eli Lilly's $7 billion acquisition of in vivo CAR-T company"

GENSCRIPT BIO(01548) rose more than 8% in early trading, up 6.84% as of the time of writing, at HK$14.68, with a trading volume of HK$1.07 billion. On the news front, Eli Lilly officially announced the acquisition of Boston biotechnology company Kelonia for an upfront payment of $3.25 billion and a total consideration of up to $7 billion. It is reported that Kelonia's core technology iGPS is an in vivo CAR-T platform based on modified lentivirus vectors. Guotai Haitong pointed out that in vivo CAR-T has advantages such as simplified manufacturing, improved accessibility, and strong platform scalability, and continues to be optimistic about it becoming an important direction for the next generation of cell therapy. Publicly available information shows that Legend Biotech's in vivo CAR-T project LVIVO-TaVec100 (CD19/CD20 dual-target in vivo CAR-T cell therapy) started Phase IIA clinical trials in May 2025. The dual specificity strategy in target design offers differentiated advantages and can reduce the risk of immune evasion by tumor cells due to the loss of a single antigen.